重组干扰素α2b联合布地奈德、异丙托溴铵雾化治疗小儿毛细支气管炎疗效观察  

Therapeutic effect of recombinant interferon alpha 2b combined with budesonide and ipratropium bromide on infantile bronchiolitis

作　　者：黄亚平[1] 牛文泽[1] 黄卫良[1] 周新华[1] HUANG Yaping;NIU Wenze;HUANG Weiliang;ZHOU Xinhua(Department of Pediatrics,Changshou City Second People＇s Hospital,Changshu 215500,Jiangsu Province,China)

机构地区：[1]常熟市第二人民医院儿科,江苏常熟215500

出　　处：《解放军医学院学报》2018年第8期688-690,722,共4页Academic Journal of Chinese PLA Medical School

摘　　要：目的研究重组干扰素α2b联合布地奈德、异丙托溴铵雾化吸入治疗小儿毛细支气管炎的效果。方法选取2016年9月-2017年9月我院儿科确诊为毛细支气管炎的患儿130例,根据随机数字表法分为观察组66例,采用重组干扰素α2b雾吸联合布地奈德+异丙托溴铵治疗,持续给药1周;对照组64例,行常规抗感染治疗雾化吸入,若患儿发生缺氧症状,及时给予吸氧支持。观察两组患儿治疗后的体征、疗效、合胞病毒(respiratory syncytial virus,RSV)及偏肺病毒(human metapneumovirus,h MPV)的水平。结果观察组患儿阳性症状、体征恢复正常时间大多短于对照组[湿啰音:(5.12±1.08)d vs(4.48±1.01)d;气喘:(2.29±0.63)d vs(3.52±0.80)d;咳嗽:(3.20±0.83)d vs(4.32±0.90)d;体温恢复正常:(18.0±2.5)h vs(27.2±2.5)h;P均<0.05];观察组患儿治疗总有效率为89.39%,显著高于对照组的70.31%(P=0.000);两组患儿治疗前的血清RSV、h MPV水平差异无统计学意义(P均>0.05);治疗后观察组患儿的RSV[(0.48±0.07)mmol/L vs(0.83±0.20)mmol/L,P=0.000)、h MPV水平(0.59±0.42)mmol/L vs(1.77±0.48)mmol/L,P=0.000)]明显低于对照组。结论重组干扰素α2b联合布地奈德、异丙托溴铵雾化吸入治疗小儿毛细支气管炎临床疗效显著,可有效缓解患儿体内炎症,缩短病程。Objective To study the effectiveness of recombinant interferon alpha 2b combined with budesonide and ipratropium bromide inhalation in the treatment of infantile bronchiolitis. Methods One hundred and thirty cases diagnosed with bronchiolitis in our hospital from September 2016 to September 2017 were randomly divided into observation group（n=66） and control group（n=64）. Patients in observation group were treated with recombinant interferon alpha 2b inhalation combined with budesonide plus ipratropium bromide for 1 week, and the control group with routine anti-infection inhalation treatment. When symptoms of hypoxia appeared, oxygen inhalation was given in time. The signs, curative effect, syncytial virus RSV and h MPV infection of the two groups were observed and compared. Results In terms of asthma, time to cough disappearance and time to temperature returned to normal, patients in observation group were superior to the control group [（2.29±0.63） d vs（3.52±0.80） d;（3.20±0.83） d vs（4.32±0.90） d;（18.0±2.5） h vs（27.2±2.5） h; all P 0.05], and the total effective rate of the observation group was significantly higher than that of the control group（89.39% vs 70.31%, P 0.05）. There was no significant difference in serum RSV and h MPV levels between the two groups before treatment（all P 0.05）, while they were significantly lower in the observation group compared to those of the control group [（0.48±0.07） mmol/L vs（0.83±0.20） mmol/L, P=0.000;（0.59±0.42） mmol/L vs（1.77±0.48） mmol/L, P=0.000]. Conclusion Recombinant interferon alpha 2b combined with budesonide and ipratropium bromide is effective in treating children with bronchiolitis, which can effectively relieve the inflammation reaction and shorten the course of the disease.

关 键 词：小儿毛细支气管炎 重组干扰素α2b 布地奈德 异丙托溴铵 

分 类 号：R725.6[医药卫生—儿科]